MIF and D-DT (aka MIF-2) are pathogenic cytokines involved in cancer progression which may serve at novel immune checkpoints. Dual MIF and D-DT targeting in oncology has shown to be an effective therapeutic which further synergies with existing immune checkpoint inhibitors in multiple pre-clinical animal models. We are developing a dual MIF/D-DT antibody for therapeutic use.